Nodular thyroid disease affects approximately 68% of the population, predominantly women, with up to 35% of nodules hiding thyroid tumors, where papillary thyroid carcinoma (PTC) is the most frequent in young adults. The identification of these cases is based on… Leggi tutto ultrasound (US) and cytological evaluation by fine needle aspiration (FNA), but still presents gray areas of diagnostic uncertainty. In this context, the category of non-invasive follicular tumors with papillary-like nuclear features (NIFTP), recently introduced as a less aggressive alternative to PTC, imposes an important update of our diagnostic schemes. Previous experiences had already tried to identify characteristics capable of distinguishing NIFTP from PTC, with the aim of improving the surgical management of these cases to avoid diagnostic thyroidectomies ("thyroid carnage"), but this has not yet significantly contributed to the routine histopathological diagnostics. The introduction of Artificial Intelligence (AI) and computational pathology (CP) has recently demonstrated the ability to discriminate NIFTP from benign nuclei and PTC on histology (NUTSHELL: NUclei from Thyroid tumors Segmentation to Highlight Encapsulated Low-malignant Lesions) , enabling the definition of human interpretable features (HIF) and the development of a classification system to assist the pathologist on whole slide images (WSI) after surgery. The aim of the CLARIFAI project is to improve pre-surgical FNA classification of thyroid lesions through a nuclear classifier and HIF introduced with AI and digital pathology. To achieve this goal, the next steps are to apply this computational tool on preoperative thyroid cytology samples to aid pathologists in distinguishing NIFTP cases from PTC cases. For this two different approaches will be adopted: - extension of the capabilities of the already consolidated histology-based classifier NUTSHELL on cytological samples; - application of multiple instance learning (MIL) on labeled cytology samples

Chemotherapy can involve lengthy treatment sessions, lasting up to several hours. Such a duration, spent in an overly medicalized setting, can induce in the patients a monopolizing focus on their pathology, which leads to a substantial decrease in their mental well-being. One way… Leggi tutto to alleviate the impact of long chemotherapy sessions would be accelerating subjective time passage as perceived by the patients, therefore making the treatment seemingly end more quickly. Stemming from the ERC Advanced Grant AN-ICON, the TIMELAPSE project proposes to prototype, test, and launch on the market a virtual reality (VR) application that will accelerate subjective time passage during chemotherapy. The idea, whose singular aspects were the object of previous scientific evidence, was so far not implemented comprehensively. TIMELAPSE will fill this R&D gap with unprecedented methods and targets, adopting a patient-centred approach to innovatively incorporate in the conception of the VR application the irreplaceable perspective of its end-users: the oncologic patients. TIMELAPSE will take this idea to proof of concept by means of five subsequent phases: 1. Theoretical elaboration, to shape a theoretical hypothesis concerning what types of VR content might accelerate subjective time passage during chemotherapy; 2. Participatory design, to refine this hypothesis by incorporating the users’ perspective; 3. Production, to develop the content for the VR application, to obtain a prototype ready to be tested. 4. Assessment, to demonstrate the tolerability and effectiveness of the VR application; and 5. Pre-commercialization, to prepare the launch of the VR application on the market. To ensure appropriate methodological tools for each phase, TIMELAPSE will rely on a collaboration between three actors: a core research group (part of the AN-ICON team); an industrial partner expert in VR applications; and a clinical partner with substantial expertise in cancer treatment.Chemotherapy can involve lengthy treatment sessions, lasting up to several hours. Such a duration, spent in an overly medicalized setting, can induce in the patients a monopolizing focus on their pathology, which leads to a substantial decrease in their mental well-being. One way to alleviate the impact of long chemotherapy sessions would be accelerating subjective time passage as perceived by the patients, therefore making the treatment seemingly end more quickly. Stemming from the ERC Advanced Grant AN-ICON, the TIMELAPSE project proposes to prototype, test, and launch on the market a virtual reality (VR) application that will accelerate subjective time passage during chemotherapy. The idea, whose singular aspects were the object of previous scientific evidence, was so far not implemented comprehensively. TIMELAPSE will fill this R&D gap with unprecedented methods and targets, adopting a patient-centred approach to innovatively incorporate in the conception of the VR application the irreplaceable perspective of its end-users: the oncologic patients. TIMELAPSE will take this idea to proof of concept by means of five subsequent phases: 1. Theoretical elaboration, to shape a theoretical hypothesis concerning what types of VR content might accelerate subjective time passage during chemotherapy; 2. Participatory design, to refine this hypothesis by incorporating the users’ perspective; 3. Production, to develop the content for the VR application, to obtain a prototype ready to be tested. 4. Assessment, to demonstrate the tolerability and effectiveness of the VR application; and 5. Pre-commercialization, to prepare the launch of the VR application on the market. To ensure appropriate methodological tools for each phase, TIMELAPSE will rely on a collaboration between three actors: a core research group (part of the AN-ICON team); an industrial partner expert in VR applications; and a clinical partner with substantial expertise in cancer treatment.Chemotherapy can involve lengthy treatment sessions, lasting up to several hours. Such a duration, spent in an overly medicalized setting, can induce in the patients a monopolizing focus on their pathology, which leads to a substantial decrease in their mental well-being. One way to alleviate the impact of long chemotherapy sessions would be accelerating subjective time passage as perceived by the patients, therefore making the treatment seemingly end more quickly. Stemming from the ERC Advanced Grant AN-ICON, the TIMELAPSE project proposes to prototype, test, and launch on the market a virtual reality (VR) application that will accelerate subjective time passage during chemotherapy. The idea, whose singular aspects were the object of previous scientific evidence, was so far not implemented comprehensively. TIMELAPSE will fill this R&D gap with unprecedented methods and targets, adopting a patient-centred approach to innovatively incorporate in the conception of the VR application the irreplaceable perspective of its end-users: the oncologic patients. TIMELAPSE will take this idea to proof of concept by means of five subsequent phases: 1. Theoretical elaboration, to shape a theoretical hypothesis concerning what types of VR content might accelerate subjective time passage during chemotherapy; 2. Participatory design, to refine this hypothesis by incorporating the users’ perspective; 3. Production, to develop the content for the VR application, to obtain a prototype ready to be tested. 4. Assessment, to demonstrate the tolerability and effectiveness of the VR application; and 5. Pre-commercialization, to prepare the launch of the VR application on the market. To ensure appropriate methodological tools for each phase, TIMELAPSE will rely on a collaboration between three actors: a core research group (part of the AN-ICON team); an industrial partner expert in VR applications; and a clinical partner with substantial expertise in cancer treatment.

Since its creation, the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC) has made a remarkable contribution to European and international cutting-edge research, as one of the largest RI for health research and in life sciences in Europe.… Leggi tutto 2023 marking its 10-year anniversary, BBMRI-ERIC is facing a unique moment to look into the long-term future and to develop its strategy for the next decade to ensure long-term sustainability. The EvolveBBMRI project aims to further develop BBMRI-ERIC for the benefit of its scientific communities and users, increase its capacity to serve EU policy priorities and further deepen its collaboration with industry. The project is structured in four thematic pillars: 1) Acceleration of datafication of biobanks and biomolecular resources to enable reproducible advanced medical research in support of EU health priorities ; 2) Teaming with industry towards greener biobanking; 3) Long-term sustainability measures for BBMRI addressing also RI landscape gaps; and 4) Strengthened approach for career paths, training and outreach activities to maximise impact. The project will ensure the implementation of specific results on 6 key target groups: a) Scientific community (Universities, Hospitals, Research Institutes); b) BBMRI-ERIC National Nodes, Biobanks in Europe and beyond; c) Industry and private foundations; d) Policy- and decision-makers at national and European levels; e) European and International networks and f) Donors, Patients and Citizens. EvolveBBMRI activities and outputs within its four Pillars will increase the long-term sustainability of BBMRI-ERIC and will thus contribute to a better structured and strengthened European research infrastructure landscape. Ultimately, the project will contribute to increase the scientific excellence to better tackle scientific and societal challenges and to expand and secure global competitiveness of the European Research Area

In line with the current guidelines for Safe and Sustainable by Design (SSbD) chemicals and materials, INTEGRANO proposes a general assessment approach based on quantitative evidence to be applied in practice for specific Nano Materials (NMs) design cases referred… Leggi tutto to inorganic, organic and carbon NMs. The development NMs dedicated novel impact categories (ICs) for nano-toxicity and eco-nanotoxicity assessment will enable the integrated application of standardised assessment methodologies. The following four NMs Life Cycle Stages (LCS) are addressed: synthesis, incorporation, use phase and end-of-life. The application of the stage-gate SSbD process through the LCS addresses performance in the five dimensions (5D s): Safety, Environmental, Economic, Social and Functional. Generation of dedicated response functions will allow associating Key Decision Factors (KDFs, such as: concentrations, processing parameters, etc.) to Key Performance Indicators (KPIs, such as: occupational safety, CO2 emissions, job creation potential, NM cost, antibacterial functionality, etc.). SSbD NMs solutions will be obtained by Multi Objective Optimisation Design (MOOD) dedicated algorithm. A dedicated digital Decision Support Toolbox (DST) will elaborate design case specific data and run MOOD algorithm to sort the set of multi-optimal SSbD options, which are simultaneously complying with all the targeted KPIs referred to the 5Ds. The digital supported decision process will help scientists, material engineers, Nano-Enabled Products (NEPs) designers, policymakers and decision-makers to takle the SSbD challenge, allowing for dramatic reduction of Research & Development (RTD) and approval leadtime as well as minimising costs and increasing the transparency of the data, by making the industrial uptake of nanotechnologies more sustainable and viable. INTEGRANO allows the integration with other existing SSbD frameworks by transposing results into other scoring metrics and enabling data exchange.

Which biomarker(s) are best suited to overcome current MRI interpretive issues and poor specificity in monitoring the effective response to therapy and the prediction of ARIA events? Irrespective of current legit debates on the clinical efficacy of amyloid-lowering therapeutics, several monoclonal antibodies… Leggi tutto (mAbs) are currently in clinical trials pipeline , including anti-TREM2 antagoist mAbs, or have entered accelerated FDA approval pathway. This means that 3 to 4 mAbs could potentially enter clinical practice in 2023. However, all of these high plaque-removing mAbs reported a common dose- and time-dependent incidence of ARIAs in up to 55% of the treated patients. In this framework, in order to minimize the risk of ARIAs, current trials limit enrollment to an extremely well-selected and radiographically monitored subpopulation of AD patients. Common criteria are the exclusion of patients with =5 cerebral microbleeds or cortical superficial siderosis at baseline and a control MRI before each biweekly/monthly infusion. This issue is challanging the generalizability of trials results, in particular concerning potential increased safety issues in real-word clinical settings. With 139 million of AD esteemed by 2050, and 60% of them living in low- and middle-income countries (2021 WHO report), longitudinal MRI monitoring plans for ARIA will hugely affect healthcare systems. This will potentially increase disparities, limiting accessibility to these therapeutics only to reach people and countries. In this framework, less costly and more accessible biomarkers will be of paramount importance for the future of AD immunotherapy. The UNIMIB-ARIA Toolkit Project aims at: 1) increase knowledge on the emerging evidence for neuroinflammation in the pathophysiology of ARIAs. 2) validate fluid-based biomarkers for improving diagnosis, prognosis, response to treatment, and prediction of ARIA-E recurrence compared to current state-of-the-art MRI images markers Thanks to the capillary activity and promotion we did in the last 10 years, including educational activities, at UNIMIB we are the National HUB for CAA and CAA-ri, receiving patients from almost all the main National centers (Spokes), the latter working as sub-spokes at regional and sub-regional level, in order to catch any patient also from very remote and rural areas. For these reasons, the National (Italy) biorepository should be considered an extremely excellent representation of the real-world clinical setting of the whole country. A gender-balanced Team (50% Female, 50% Male) of self-motivated and enthusiastic early career and young researcher composes the Teamwork. Addressing the aims of the UNIMIB-ARIA Project will be of paramount importance to increase generalizability and limit unnecessary restrictions to the future access of AD Therapeutics by the broaden community of AD and CAA patients, as well as to guide secondgeneration of more effective and safe therapeutics.